JINYU(SH:600201) Zheng Quan Ri Bao Wang·2026-02-01 12:00Core Viewpoint - The successful completion of the first round of clinical trials for the African Swine Fever (ASF) subunit vaccine by Jinyu Biotechnology Co., Ltd. marks a historic milestone in the animal vaccine industry, providing a potential solution to a long-standing issue in global pig farming [1][2]. Group 1: Vaccine Development - The ASF virus has caused over 1 trillion yuan in economic losses to China's pig farming industry since its introduction in 2018, highlighting the urgent need for effective vaccines [2]. - Jinyu Biotechnology has invested nearly 600 million yuan over seven years in developing various vaccine technologies, including gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2]. - The ASF subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs on July 14, 2025, becoming the first of its kind to enter clinical trials in China [2]. Group 2: Clinical Trial Results - The first round of challenge experiments concluded successfully in January 2026, showing a 100% survival rate in the immunized group, while the control group experienced a 100% mortality rate [3]. - The vaccine utilizes a genetically engineered subunit technology that expresses eight conserved antigen proteins without live virus, eliminating the risk of virulence reversion [3]. - The vaccine's target has a 99.7% homology with currently circulating recombinant strains, enhancing its effectiveness [3]. Group 3: Technological Integration - The success of the ASF vaccine reflects the integration of AI and biotechnology, with AI accelerating antigen screening and structural optimization [4]. - Jinyu Biotechnology has established the world's first high-throughput target library for ASF, evaluating over 100 proteins to ensure the scientific and effective design of the vaccine [4]. - The company has invested 230 million yuan to build a dedicated GMP production line with an annual capacity of 300 million doses, ensuring consistency from trial to commercialization [4]. Group 4: Future Developments - Jinyu Biotechnology aims to provide a comprehensive solution that includes smart testing, veterinary services, immune purification, and branded food products, moving beyond just vaccine sales [4][5]. - The company is also advancing other innovative vaccines, including an mRNA vaccine for feline infectious peritonitis and a novel mycoplasma vaccine for cattle, which has already been launched [5]. - Future plans include accelerating the registration process for the ASF subunit vaccine and expanding the mRNA vaccine product pipeline, while increasing investments in Southeast Asia to scale up technology, products, and services [5].